Raiffeisen Bank International AG Has $723,000 Stock Position in Sarepta Therapeutics, Inc. $SRPT

Raiffeisen Bank International AG boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 137.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,465 shares of the biotechnology company’s stock after purchasing an additional 24,000 shares during the quarter. Raiffeisen Bank International AG’s holdings in Sarepta Therapeutics were worth $723,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Y Intercept Hong Kong Ltd raised its position in shares of Sarepta Therapeutics by 421.3% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 47,382 shares of the biotechnology company’s stock valued at $3,024,000 after buying an additional 38,292 shares in the last quarter. Tempus Wealth Planning LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $229,000. Maridea Wealth Management LLC increased its stake in Sarepta Therapeutics by 101.8% in the first quarter. Maridea Wealth Management LLC now owns 9,147 shares of the biotechnology company’s stock valued at $584,000 after acquiring an additional 4,614 shares during the last quarter. Hurley Capital LLC raised its position in Sarepta Therapeutics by 139.2% during the first quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 835 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in Sarepta Therapeutics during the first quarter worth $1,458,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $17.44 on Wednesday. The stock has a 50-day moving average price of $20.25 and a two-hundred day moving average price of $23.26. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $138.81. The company has a market capitalization of $1.83 billion, a PE ratio of -20.05 and a beta of 0.52. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). The firm had revenue of $399.36 million for the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business’s revenue for the quarter was down 14.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. Analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SRPT shares. Morgan Stanley raised their target price on Sarepta Therapeutics from $15.00 to $20.00 and gave the company an “equal weight” rating in a report on Tuesday, July 29th. Citigroup began coverage on Sarepta Therapeutics in a research report on Tuesday, July 22nd. They set a “sell” rating for the company. Royal Bank Of Canada raised their price objective on Sarepta Therapeutics from $14.00 to $16.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 8th. Oppenheimer raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $30.00 to $37.00 in a research note on Tuesday, July 29th. Finally, Leerink Partners increased their target price on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a “market perform” rating in a report on Tuesday, September 9th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Hold” and a consensus price target of $33.75.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.